ctDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)

Colon Cancer Clinical Trial

— REVISE  

Official title:

Value of ctDNA in Surveillance of Chemosensitivity and Regimen Adjustment in Stage III Colon Cancer: a Phase II Randomized Controlled Trial (REVISE Trial)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06242418
• Other study ID #: 2023#1998
• Status: Recruiting
• Phase: Phase 2
• Start date: March 25, 2024
• Est. completion date: December 31, 2026

Study information

• Verified date: March 2024
• Source: West China Hospital
• Contact: Ziqiang Wang
• Phone: +8685422480
• Email: wangziqiang[@]scu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Colon cancer is one of the most common malignant tumors with an increasing incidence rate in China. Surgical resection is still the main treatment for colon cancer at present. Radical surgery followed by three/six months chemotherapy is the standard of care for stage III colon cancer; however, patients with different risk factors have different prognosis. The IDEA trial divided stage III colon cancer patients into low-risk (T1-3/N1) and high-risk (T4 or N2) groups, and showed that for some low-risk patients, three months chemotherapy did not decrease survival outcomes, while for some high-risk patients, the recurrence risk was still high even after six months chemotherapy. Therefore, it's worth to explore other risk stratification factors beyond T and N stage for these patients.

Circulating tumor DNA (ctDNA) is derived from cancer cells and can be detected in blood. Literatures have reported that ctDNA can be used for tumor diagnosis, therapeutic monitoring, and prognosis assessment in multiple cancers, including colon cancer. The GERCOR-PRODIGE trial, an accompanying study of IDEA, reported that in the high-risk group of stage III colon cancer, patients with ctDNA-positive and receiving six months chemotherapy had similar prognosis to these with ctDNA-negative and receiving three months chemotherapy; in the low-risk group, patients with ctDNA-negative and receiving three or six months chemotherapy had similar prognosis to patients with ctDNA-positive and receiving 6 months chemotherapy, but patients with ctDNA-positive and receiving three months chemotherapy had the worst prognosis. The results of this trial suggests that ctDNA can be potentially used as a further stratification factor to guide adjuvant chemotherapy for stage III colon cancer.

Several RCTs have shown that double-drug regimens chemotherapy based on oxaliplatin (FOLFOX and XELOX) can improve the prognosis of patients with stage III colon cancer. Therefore, the ESMO, NCCN, and CSCO guidelines recommend FOLFOX or XELOX for stage III colon cancer. The 2-year disease-free survival rate of these patients who received FOLFOX or XELOX chemotherapy was about 80%. It is worth to further explore how to improve the prognosis of these patients. Recently, the triple-drug regimens of oxaliplatin, irinotecan, and fluoropyrimidine (FOLFOXIRI) has been found to be superior to FOLFOX or XELOX for metastatic colorectal cancer in terms of response rate and survival. Currently, research on FOLFOXIRI plus targeted therapy in metastatic colorectal cancer is progressing rapidly, but there is little research on the use of FOLFOXIRI as adjuvant chemotherapy for stage III colon cancer. There is an ongoing international multicenter phase III RCT comparing FOLFOXIRI and FOLFOX6 adjuvant chemotherapy for high-risk stage III colon cancer patients, but it did not further stratify patients based on postoperative ctDNA status, which may result in some patients receiving excessive chemotherapy.

The present study plans to enroll patients with stage III colon cancer with positive ctDNA within 1 month after surgery. These patients will receive 2 cycles of XELOX chemotherapy followed by retesting ctDNA. During the waiting period of the ctDNA results (approximately 3 weeks due to the testing time), all patients will receive another cycle of XELOX chemotherapy. If the ctDNA remains positive, the patients will be randomly assigned to receive 8 cycles of FOLFOXIRI as intensified adjuvant chemotherapy or 5 cycles of XELOX regimen as standard adjuvant chemotherapy. If the ctDNA is negative, the patients will continue to receive 5 cycles of XELOX chemotherapy. Within 3 weeks after the completion or termination of chemotherapy, ctDNA will be retested again. The aims of this study are to explore the value of ctDNA in surveillance of chemosensitivity and to preliminarily evaluate whether the intensified chemotherapy with FOLFOXIRI can increase ctDNA clearance as well as its safety in stage III colon cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age 18-75 years, regardless of gender.

• Tumor located in the colon (the distance from the lower margin of the tumor to the anus is greater than 12 cm).

• Radical surgery performed, and the postoperative pathological staging is stage III, i.e., T1-4N1-2M0 (AJCC TNM staging, 8th edition, 2017).

• No local or distant tumor recurrence was found in imaging examination. ? ECOG performance status: 0-1. ? No history of allergy to fluoropyrimidines or platinum-based drugs.

• Voluntarily participating in this study, signing an informed consent form, good compliance, and cooperation with follow-up.

Exclusion Criteria:

• History of other malignant tumors within the past five years (excluding basal cell carcinoma and/or cervical carcinoma in situ after radical surgery).

• Previous chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc., for colon cancer.

• Patients suspected or confirmed to have lynch syndrome. ? Severe cardiovascular or cerebrovascular diseases, liver or kidney dysfunction, severe primary hematological diseases, etc.

• Allergy to fluoropyrimidines or platinum-based drugs.

? Any unstable condition or situation that may harm patient safety or compliance with the study, such as fertility needs, pregnancy, breastfeeding, depression, bipolar disorder, obsessive-compulsive disorder, or schizophrenia.

? Patients deemed unsuitable for participation in this study by the investigator.

? Recently participated in or currently participating in other clinical trials of drugs.

Related Conditions & MeSH terms

• Colon Cancer
• Colonic Neoplasms

Intervention

Drug:
• FOLFOXIRI
Eight cycles of FOLFOXIRI: Oxaliplatin 85mg/m2 ivgtt over 2 hours on day 1, Irinotecan 165mg/m2 ivgtt over 90 minutes on day 1, Calcium folinate 400mg/m2 ivgtt over 2 hours on day 1, 5-Fluorouracil 2400mg/m2 civ48h; Each cycle lasts for 2 weeks.
• XELOX
Five cycles of XELOX: Oxaliplatin 130mg/m2 on day 1, Capecitabine 1000mg/m2 bid from day 1 to day 14; Each cycle lasts for 3 weeks.

Locations

Country	Name	City	State
China	West China Hospital of Sichuan University	Chengde	Sichuan
China	People's Hospital of Sichuan Province	Chengdu	Sichuan
China	Shang Jin Hospital of West China Hospital, Sichuan University	Chengdu	Sichuan
China	Sichuan Cancer Hospital	Chengdu	Sichuan
China	The Third People's Hospital of Chengdu	Chengdu	Sichuan
China	West China Tianfu Hospital, Sichuan University	Chengdu	Sichuan
China	The Affiliated Hospital of Guizhou Medical University	Guiyang	Guizhou
China	First Affiliated Hospital of Kunming Medical University	Kunming	Yunnan
China	Yunnan Cancer Hospital	Kunming	Yunnan

Sponsors (2)

Lead Sponsor	Collaborator
West China Hospital	GeneCast Biotechnology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in value of ctDNA concentration	Defined as the change in value of ctDNA measured after 2 cycles of XELOX (ctDNA2) and after the completion or termination of chemotherapy (ctDNA3). ?ctDNA= ctDNA3 - ctDNA2.	six months
Secondary	ctDNA clearance rate	Defined as the proportion of patients whose ctDNA becomes negative after the completion or termination of chemotherapy to the total patient.	six months
Secondary	disease-free survival	The time from randomization to local recurrence, distant metastasis, or death.	two years
Secondary	metastasis-free survival	The time from randomization to distant metastasis.	two years
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE 5.0.	Number of participants with treatment-related adverse events as assessed by CTCAE 5.0.	two years
Secondary	quality of life as assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).	The EORTC QLQ-C30 consists of 30 items, including 5 functional scales (physical function, role function, cognitive function, emotional function, social function), 3 symptom scales (fatigue, pain, nausea and vomiting), 6 individual measurement items (dysphagia, loss of appetite, sleep disorders, constipation, diarrhea, economic difficulties), and 1 patient self-assessment item (overall health status). Each of the first 28 items score 1 to 4. The higher the score, the worse the quality of life. The last 2 items score 1 to 7. The higher the score, the best the quality of life.	two years